Gene Therapy for Achromatopsia (CNGB3)

Completed · Phase 1/Phase 2

Conditions studied: Achromatopsia

In brief

A clinical trial of AAV - CNGB3 retinal gene therapy for patients with achromatopsia

Key facts

Study ID

NCT03001310

Run by

MeiraGTx UK II Ltd

People needed

23

Starts

2017-01-16

Expected to finish

2019-10-25

Last updated by the study team

2023-03-08

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are aged 3 years or older
• Have achromatopsia confirmed by a retinal specialist (CI or PI)

You may not qualify if…

• Are females who are pregnant or breastfeeding
• Have participated in another research study involving an investigational medicinal therapy for ocular disease within the last 6 months
• Have any other condition that the CI/PI considers makes them inappropriate for entry into the trial

Where it is running

• University of Michigan Kellog Eye Centre — Ann Arbor, Michigan, United States
• Moorfields Eye Hospital NHS Foundation Trust — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.